CAMP4 Therapeutics is targeting regulatory RNA, whose role in gene expression was first described by co-founder and MIT Professor Richard Young.

Cue applied technology it initially tested in the treatment of cancers to the development of CUE-501. The idea is to make B cells appear as if they are infected with a virus such as cytomegalovirus or SARS-CoV-2.

Here’s how real scientists are effectively preparing to battle fungus today.

CorVista is bringing AI to bear on cardiac diagnostics, helping hospitals and doctors identify who need the most care.

John Kane, MD, shared new positive phase 2 data on N-methyl amisulpride (LB-102) for the treatment of patients with acutely exacerbated schizophrenia at the 2025 Annual Congress of the Schizophrenia International Research Society.

Dr Carsten Rudolph, Cofounder and Chief Executive Officer at Ethris, said that from a partnering perspective, he observed some shifts in trends.

Many drug manufacturers, healthcare providers, and patients see the potential benefits of producing autologous therapies at the point of care (POC). However, even among its proponents, there is less agreement on the best path forward, says AltruBio CEO Judy Chou, Ph.D.

Raj shares his journey from big pharma to biotech entrepreneurship, the science behind Rectify’s groundbreaking approach to drugging membrane proteins, and how his team is tackling rare hepatobiliary diseases with small-molecule therapies.